Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | ACACB | O00763 | 10/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.63 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741212 | 1.00 | NPC1 (0.76) | NPC1RAB9ALMNAACACBTAAR1 | |
| SCHEMBL7609323 | 1.00 | NPC1 (0.76) | NPC1RAB9ALMNAACACBTAAR1 | |
| SCHEMBL12001230 | 0.90 | ACACB (0.83) | NPC1RAB9ALMNAACACB | |
| SCHEMBL8471790 | 0.89 | KMT2A (0.72) | NPC1RAB9ALMNAACACB | |
| SCHEMBL31545865 | 0.87 | NPC1 (0.69) | NPC1RAB9ALMNAACACBTAAR1 | |
| SCHEMBL24609344 | 0.86 | NPC1 (0.79) | NPC1RAB9ALMNATAAR1 | |
| SCHEMBL14654946 | 0.86 | NPC1 (1.00) | NPC1RAB9ALMNATAAR1 | |
| SCHEMBL2543698 | 0.86 | NPC1 (0.79) | NPC1RAB9ALMNATAAR1 | |
| Hydrochloric Acid SCHEMBL4323384 | 0.85 | NPC1 (0.76) | NPC1RAB9ALMNATAAR1 | |
| SCHEMBL825426 | 0.84 | ACACB (0.83) | LMNAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968198-B1 | STABLE TRANSDERMAL AMPHETAMINE COMPOSITIONS AND METHODS OF MANUFACTURE | NOVEN PHARMA (US) | 2018-11-21 | — | — | EP | claimed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-112334454-B | Environment-friendly olefin hydration reaction | 佐治亚州立大学研究基金会公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220370619-A1 | STABLE TRANSDERMAL AMPHETAMINE COMPOSITIONS AND METHODS OF MANUFACTURE | NOVEN PHARMACEUTICALS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-11376327-B2 | Stable transdermal amphetamine compositions and methods of manufacture | NOVEN PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-1442006-A2 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | Boehringer Ingelheim Chemicals, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037843-A2 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-6399828-B1 | ACYLATION OF PHENYLPROPANOLAMINE; CATALYTIC HYDROGENATION | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-0820984-B1 | Activated amphetamines | ROCHE DIAGNOSTICS GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-0820984-A1 | Activated amphetamines | Roche Diagnostics GmbH (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0801083-A2 | Improved functionalized resin for chemical synthesis | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0011858-B1 | RADIOIODINE CONTAINING AMINES, THEIR PREPARATION AND THEIR USE AS BRAIN IMAGING AGENTS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-05-18 | — | — | EP | disclosed |
| US-4360511-A | Amines useful as brain imaging agents | MEDI-PHYSICS, INC. (US) | 1982-11-23 | — | — | US | disclosed |
| US-4329281-A | AMPHETAMINE, METHAMPHETAMINE | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| EP-0011858-A1 | Radioiodine containing amines, their preparation and their use as brain imaging agents | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | NPC1 1079/4885RAB9A 700/4885LMNA 4850/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | NPC1 1400/4885RAB9A 527/4885LMNA 4876/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | NPC1 1400/4885RAB9A 527/4885LMNA 4876/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | NPC1 1205/4885RAB9A 580/4885LMNA 4869/4885 |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | HAO2, AHR, HMOX1 | NPC1 2480/4885RAB9A 2754/4885LMNA 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.